Time will tell if my timing is poor or awesome. As you know, I've been watching this one since I figured it was a prime takeout target back in what was it... Nov 2017?
There is no way this is not being seen through to FDA approval. Delcath has patented a concept and a delivery system. That system can be targeted to different cancers.
There are many roads to recovery. Cancer is not treated in one way. Anyone saying this is a one trick pony doesn't get it.
Once the $25 Million Line of Credit is granted (with oversight), the shares here will spike. No way this company is worth less than $150 Million and that is on the SUPER conservative side.
Never underestimate how cheap a finance co will try to drop the price before COMMITTING CAPITAL. This went way lower than I expected but it looks to be within range at this point for NEWS on the LOC. Accumulation is about to get REAL.
News 
Market Data 
Discover 
